FDA's acceptance of Novartis AG’s biosimilar version of Amgen Inc.’s neutropenia mainstay Neulasta (pegfilgrastim) puts the company in the running to bring its second biosimilar to the US market.
Novartis' Sandoz Inc. generic drug unit revealed the acceptance of the filing on Nov. 18. Under the 10-month review...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?